258 related articles for article (PubMed ID: 34619078)
1. A selective antibiotic for Lyme disease.
Leimer N; Wu X; Imai Y; Morrissette M; Pitt N; Favre-Godal Q; Iinishi A; Jain S; Caboni M; Leus IV; Bonifay V; Niles S; Bargabos R; Ghiglieri M; Corsetti R; Krumpoch M; Fox G; Son S; Klepacki D; Polikanov YS; Freliech CA; McCarthy JE; Edmondson DG; Norris SJ; D'Onofrio A; Hu LT; Zgurskaya HI; Lewis K
Cell; 2021 Oct; 184(21):5405-5418.e16. PubMed ID: 34619078
[TBL] [Abstract][Full Text] [Related]
2. Hygromycin A in the Lymelight.
Arnaboldi PM; Narasimhan S
Cell Host Microbe; 2021 Nov; 29(11):1599-1601. PubMed ID: 34762823
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidases from Borrelia burgdorferi: Antibiotic targets for Lyme disease.
Cornell KA; Knippel RJ; Cortright GR; Fonken M; Guerrero C; Hall AR; Mitchell KA; Thurston JH; Erstad P; Tao A; Xu D; Parveen N
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129455. PubMed ID: 31669585
[TBL] [Abstract][Full Text] [Related]
4. Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.
Sharma B; Brown AV; Matluck NE; Hu LT; Lewis K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4616-24. PubMed ID: 26014929
[TBL] [Abstract][Full Text] [Related]
5. Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
Wu X; Sharma B; Niles S; O'Connor K; Schilling R; Matluck N; D'Onofrio A; Hu LT; Lewis K
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126963
[No Abstract] [Full Text] [Related]
6. A doxycycline hyclate rodent bait formulation for prophylaxis and treatment of tick-transmitted Borrelia burgdorferi.
Dolan MC; Zeidner NS; Gabitzsch E; Dietrich G; Borchert JN; Poché RM; Piesman J
Am J Trop Med Hyg; 2008 May; 78(5):803-5. PubMed ID: 18458316
[TBL] [Abstract][Full Text] [Related]
7. Molecular Testing of Serial Blood Specimens from Patients with Early Lyme Disease during Treatment Reveals Changing Coinfection with Mixtures of Borrelia burgdorferi Genotypes.
Mosel MR; Carolan HE; Rebman AW; Castro S; Massire C; Ecker DJ; Soloski MJ; Aucott JN; Eshoo MW
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036693
[No Abstract] [Full Text] [Related]
8. Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.
Pothineni VR; Potula HSK; Ambati A; Mallajosyula VVA; Sridharan B; Inayathullah M; Ahmed MS; Rajadas J
Sci Rep; 2020 Mar; 10(1):3798. PubMed ID: 32123189
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.
Johnson RC; Kodner CB; Jurkovich PJ; Collins JJ
Antimicrob Agents Chemother; 1990 Nov; 34(11):2133-6. PubMed ID: 2073103
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment of animals infected with Borrelia burgdorferi.
Wormser GP; Schwartz I
Clin Microbiol Rev; 2009 Jul; 22(3):387-95. PubMed ID: 19597005
[TBL] [Abstract][Full Text] [Related]
11. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.
Bockenstedt LK; Gonzalez DG; Haberman AM; Belperron AA
J Clin Invest; 2012 Jul; 122(7):2652-60. PubMed ID: 22728937
[TBL] [Abstract][Full Text] [Related]
12. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment.
Bockenstedt LK; Mao J; Hodzic E; Barthold SW; Fish D
J Infect Dis; 2002 Nov; 186(10):1430-7. PubMed ID: 12404158
[TBL] [Abstract][Full Text] [Related]
13. Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?
Hodzic E
Bosn J Basic Med Sci; 2015 Jul; 15(3):1-13. PubMed ID: 26295288
[TBL] [Abstract][Full Text] [Related]
14. Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.
Lin YP; Li L; Zhang F; Linhardt RJ
Microbiology (Reading); 2017 Dec; 163(12):1759-1766. PubMed ID: 29116038
[TBL] [Abstract][Full Text] [Related]
15. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents--possible implications for new therapeutic approaches to Lyme disease.
Hunfeld KP; Kraiczy P; Kekoukh E; Schäfer V; Brade V
Int J Med Microbiol; 2002 Jun; 291 Suppl 33():125-37. PubMed ID: 12141737
[TBL] [Abstract][Full Text] [Related]
16. Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
Feng J; Shi W; Zhang S; Zhang Y
Emerg Microbes Infect; 2015 Jun; 4(6):e31. PubMed ID: 26954881
[TBL] [Abstract][Full Text] [Related]
17. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.
Embers ME; Barthold SW; Borda JT; Bowers L; Doyle L; Hodzic E; Jacobs MB; Hasenkampf NR; Martin DS; Narasimhan S; Phillippi-Falkenstein KM; Purcell JE; Ratterree MS; Philipp MT
PLoS One; 2012; 7(1):e29914. PubMed ID: 22253822
[TBL] [Abstract][Full Text] [Related]
18. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice.
Hodzic E; Imai D; Feng S; Barthold SW
PLoS One; 2014; 9(1):e86907. PubMed ID: 24466286
[TBL] [Abstract][Full Text] [Related]
19. Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.
Pothineni VR; Wagh D; Babar MM; Inayathullah M; Solow-Cordero D; Kim KM; Samineni AV; Parekh MB; Tayebi L; Rajadas J
Drug Des Devel Ther; 2016; 10():1307-22. PubMed ID: 27103785
[TBL] [Abstract][Full Text] [Related]
20. Generality of Post-Antimicrobial Treatment Persistence of
Hodzic E; Imai DM; Escobar E
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
